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ABSTRACT
Background: The ideal therapy for ascites in liver cirrhosis is a low sodium diet and a combination of furosemide and
spironolacton. However, this still sometimes does not produce satisfactory results, even after increasing the dose of the
diuretic. Such failure occurs due to the influence of the Renin Angiotensin Aldosterone (RAA) system. Low doses of ACE
inhibitors (captopril) should improve renal blood flow and increase filtration at the glomeruli, thus increasing natriuresis
without causing haemodynamic imbalance.
Study aim: To discover the natriuretic and diuretic effects of low dose captopril adjuvant in patients with liver cirrhosis who
have received furosemide and spironolacton by measuring urinary sodium and 24-hour urine output.
Materials and method: This study was conducted on in- and out- patients with liver cirrhosis and Ascites at the Dr. Kariadi
Central Public Hospital, Semarang, who met the inclusion and exclusion criteria. The study took place from June 1st, 1997 to
March 31st, 1998, and included 40 cases of liver cirrhosis with ascites.
Study design: Open comparative randomized clinical trial with permuted blocks.
All of the patients received a low fat diet, 40 mg of furosemide, 3x50 mg of spironolacton for 2 weeks, and patients with a
urinary sodium level was below 80 mEq/L were randomized into two groups: group A receiving 3 x 6.25 mg of captopril, and
group B receiving standard therapy.
The pre- and post- treatment results for Group A were significantly different.
The pre- and post- treatment results for Group B were not significantly different.
Conclusion: Low dose (3 x 6.25 mg) captopril adjuvant in patients with liver cirrhosis and ascites who have received
standard doses of furosemide and spironolacton could increase natriuresis and diuresis without causing haemodynamic
imbalance.
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Results: 
Variable Pre- treatment Post – treatment p 
Group A :       
Urinary sodium level 
(meq/L) 
65.450 ± 16.577 109.950 ± 49.109 0.001 
24-hour urine output (cc) 1138.750 ± 480.438 1381.250 ± 394.441 0.004 
Group B:       
Urinary sodium level 
(meq/L) 
68.30 ± 12.85 91.750 ± 64.04 0.103 
24-hour urine output (cc) 1390 ± 448.27 1392.50 ± 713.46 0.988 
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INTRODUCTION
Ascites is the most common complication of liver cir-
rhosis. Ascites in a patient with liver cirrhosis is an indi-
cation for hospitalization and an indication a poor prog-
nosis, which complicates management.1
Ascites and edema in a patient with liver cirrhosis
occur through a complex mechanism that has not been
completely understood. Currently, most experts agree
that development of ascites in patients with liver cirrho-
sis depends on 2 factors: local factors that create fluid
accumulation in the abdominal cavity, and systemic fac-
tors responsible for changes in the cardiovascular and
renal system, causing fluid and sodium retention. Those
two factors are directly related with portal hypertension,
hypoalbuminemia, the sympathetic nervous system, and
renal factors through the renin angiotensin aldosterone
(RAA) system, and arginine vasopressin.2,3,4
Fluid and sodium retention reduces filtration at the
glomeruli, which in turn aggravates ascites.5,6 Continu-
ous neurohormonal activation would result in more evi-
dent changes in renal function, finally generating the
hepatorenal syndrome.2,4
Patients with mild and moderate ascites usually man-
age with conventional medical treatment in the form of
a low sodium diet of 1-1.5 gram/day and diuretics.7 A
combination of furosemide and spironolacton increases
natriuresis and diuresis and minimizes hyperkalemia due
to spironolacton.7,8 The outcome of the standard therapy
is often unsatisfactory, even with increased doses of di-
uretics, causing refractory ascites. Ascites is usually la-
beled as refractory if the patient’s body weight falls less
than 200 g/day for 4 days or if sodium excretion is less
than 50 meq/day with a dose of 400 mg/day of
spironolacton and 160 mg /day of furosemide.9
The outcome of adjuvant diuretics varies, including
towards the hepatorenal syndrome. If such treatment
fails, repeated ascites puncture is conducted, even though
this also fails to improve the patient’s survival rate.7,10
Surgical intervention is performed on 5 to 10% of pa-
tients with refractory ascites or with hepatorenal syn-
drome. Surgical intervention has an efficacy rate of
100%, with the possibility of inducing hepatic coma.2,11
Constant stimulation on the RAA system increases
diuretic requirement. Changes in the blood flow of the
renal cortex causes the diuretics to be ineffective. Sup-
pression of the RAA system by ACE inhibitors (captopril)
would improve renal blood flow.12 Low dose captopril
adjuvant would reduce the dose of the diuretics and may
be used as an alternative adjuvant therapy to the stan-
dard treatment.13 Since there are still only few studies
on this, and the authors found no reports of such study
conducted in Indonesia, we decided to perform this pre-
liminary study.
STUDY AIM
To determine the natriuretic and diuretic effects of
low dose captopril adjuvant in patients with liver cirrho-
sis and ascites who have received spironolacton and fu-
rosemide by measuring urinary sodium and 24-hour urine
output.
MATERIALS AND METHODS
The study design chosen was open comparative ran-
domized clinical trial with random permuted blocks.
The study was conducted on in- and out- patients
with liver cirrhosis and ascites at the Dr. Kariadi Central
Public Hospital, Semarang, who met the criteria, from
June 1st, 1997 until March 31st, 1998. Patients who met
the study criteria were male and female, over 18 years
of age, who suffered from liver cirrhosis and grade II or
III ascites. Drugs that could influence the outcome of
the study, such as propanolol, nitrates, and NSAIDs, were
terminated a week prior to the commencement of the
study. The patients in this study were willing to be a
volunteer for the study. Exclusion criteria were as fol-
lows: creatinine clearance of less than 30 cc/minute,
systolic blood pressure of less than 95 mmHg, incontrol-
lable infection, connective tissue disorder.
Sample size: based on literature, the success rate of
therapy is 50%. In this study, a success rate of 70% was
expected. Based on the formula, 240 subjects were re-
quired as sample.14 In this preliminary study, 40 people
were examined.
Data collection and study procedure
All patients who were included as study sample re-
ceived the following therapy for two consecutive weeks:
a low sodium diet of 1.5-2 g/day, 40 mg/day of furo-
semide, and 3x6.25 mg of spironolacton/day. On the 15th
day, the following measurements were taken: bodyweight,
blood pressure, pulse rate, abdominal circumference, 24-
hour urine volume, 24-hour urinary sodium, blood sodium,
potassium, albumin, ureum, and creatinine levels. Com-
plaints during treatment were recorded. Patients with a
urinary sodium level of less than 80 mEq/l were then
randomized.
The patients were divided into 2 groups. Group A
received an adjuvant of 3 x 6.25 mg of captopril/day.
Group B received no additional therapy. After two weeks,
the same clinical and laboratory evaluation was con-
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ducted. 
The diagnosis of liver cirrhosis was based on clinical  
findings, laboratory examinations, and ultrasound find- 
ings. The degree of cirrhosis is based on the Child-Pugh  
criteria. 
Data analysis: Collected data were then tabulated and 
coded for analysis using the SPSS statistical program 
for PC. The age, sex, complaints, and clinical findings 
were displayed descriptively. For the variables of body 
weight, abdominal circumference, blood pressure, 24- 
hour urine volume, 24-hour urinary sodium, laboratory 
evaluation before and after randomization, as well as 
the degree difference is analyzed using paired group T 
test, and is considered significant if p<0.05. 
 
RESULTS 
From June 1997 until 31 March 1998, there were 123 
patients with liver cirrhosis diagnosed. Seventy-three 
patients suffered from ascites. Forty patients met the 
inclusion criteria. The randomized Group A consisted of 
20 patients, and Group B consisted of 20 patients. 
Twenty-patients (52.5%) were male, and 19 (47.5%) 
female. The age ranged from 25 - 64 years, mostly 40 - 
49 years of age (14 patients - 35%). The average age 
for Group A was 50.35 (+ 8.89). The average age for 
Group B was 49.01 (+ 6.73). 
The most common Child - Pugh score for Group B 
was score B, in 11 patients (47.8%). The most for Group B 
was score B, in 12 patients (52.2%). No significant 
difference was found between group A and B (p > 0.05).  
 Complaints during treatment: (Table 1) 
In Group A, 5 patients complained of cough (25 %).  
Two people complained of confusion (10%) and 2 com- 
plained of itching (10%). Nausea, muscle cramps, and  
diarrhea were each reported by one person. For Group  
B: 1 person complained of cough, but the same patient  
also suffered from lung tuberculosis. One person com- 
plained of arthralgia, but the person also suffered from  
osteoarthritis. 
Table 1 Distribution of Symptoms during Treatment  
 Symptom     Group A  %  Group B  %                     Total 
Confuse 2 100.0 0 0.0 100.0 
Cough 5 83.3 1 16.7 100.0 
Athralgia 1 50.0 1 50.0 100.0 
Itching 2 100.0 0 0.0 100.0 
Nausea 1 100.0 0 0.0 100.0 
Cramp 1 100.0 0 0.0 100.0 
Diarrhea 1 100.0 0 0.0 100.0 
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The pre- and post therapy clinical parameter for group 
A can be found in Table 2, group B in Table 3. 
The systolic blood pressure for group A dropped sig- 
nificantly from 115 + 14.68 to 103.25 + 8.78 (p < 0.001). 
While the systolic blood pressure for group B showed 
an insignificant increase from 114.5 + 12.34 to 115.5 + 
11.46 (p > 0.05). 
The diastolic blood pressure for group A dropped in- 
significantly from 70.5 + 6.86 to 68.0 + 6.96 (p > 0.05). 
The diastolic blood pressure for group B did not show a 
significant increase. 
The average bodyweight for group A was reduced  
insignificantly from 55.125 + 13.487 to 53.925 + 12.113  
(p > 0.05). The average body weight in Group B was  
reduced from 52.8 + 8.41 to 51.62 + 8.72 (p>0.05). Thus,  
there was no significant difference in bodyweight re- 
duction between group A and B. Even though the aver- 
age abdominal circumference for group A and B showed  
a reduction, there was no significant difference in the  
two. (Group A from 87.80 + 12.48 to 86.25 + 11.0 (p >  
0.05) Group B from 84.0 + 7.98 to 82.88 + 7.93 (p > 
3  
 
Table 2 Clinical parameter Pre- and Post-treatment 
 (Group A) 
Variable Pre Post p 
Syst. BP 
(mmHg) 
115.500 + 
14.681 103.250 + 8.777 0.001 
Diast BP 
(mmHg) 
70.500 + 
6.863 68.0 + 6.959 0.135 
Body 
weight (kg) 
55.125 + 
13.487 53.925 + 12.113 0.148 
Abdom. 
Circ. (cm)  
87.800 + 
12.478 86.250 + 11.008 0.162 
Na-urine 
(meq/L) 
65.450 + 
16.577 
109.950 + 
49.109 0.001 
Vol.Urine 
(mL/24h)  
1138.750 + 
480.438 
1381.250 + 
394.441 0.004 
 
Table 3 Clinical parameter Pre- and Post-treatment 
 (Group B) 
Variable Pre Post p 
Syst. BP 
(mmHg) 114.5 + 12.34 115.50 + 11.46 0.58 
Diast. BP 
(mmHg) 74.00 + 5.98 75.80 + 6.05 0.19 
Body 
weight (kg) 52.80 + 8.41 51.62 + 8.72 0.25 
Abdom. 
Circ. (cm)  84.00 + 7.98 82.88 + 7.93 0.078 
Na-Urine 
(meq/l) 68.30 + 12.85 91.75 + 64.06 0.103 
Vol.Urine 
(mL/24 h)  
1390.50 + 
448.27 
1392.50 + 
713.46 0.988 
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0.05))
The urinary sodium level for group A was signifi-
cantly increased from 65.45 + 16.58 to 109.95 + 49.11
(p < 0.001). The urinary sodium level for Group B was
insignificantly increased from 68.30 + 12. 85 to 91.75 +
64.06 (p > 0.05). This shows that captopril significantly
increases natriuresis.
The average 24-hour urine volume 24 for group A
showed a significant increase from 1138.75 + 480.438
to 1381.25 + 394.44 (p < 0.05). There was no significant
change in Group B, from 1390.50 + 448.27 to 1392 +
713.46 (p > 0.05). This demonstrates a significant dif-
ference in an increase in diuresis between group A and
B.
Laboratory changes: Na, K, ureum, creatinine, albu-
min for group A can be found in table IV, and group B in
table 5. The average blood sodium level for group A
showed an insignificant change, from 138.95 + 7.326 to
141.20 + 8.97  (p > 0.05). The average blood sodium
level for group B showed an insignificant change, from
141.85 + 6.62 to 137.25 + 6.41 (p > 0.05).
The blood potassium levels for group A and B showed
a slight increase, which was insignificant. The blood ureum
level for group A increased from 42.57 + 24.67 to 56.51
+ 44.84. yet this increase was not significant (p > 0.05).
The increase in Group B was significant, from 32.99 +
12.46 to 44.09 + 20.98 (p < 0.001). The increase in blood
ureum level was significant in patients who did not re-
ceive captopril adjuvant. The average blood creatinine
for group A showed a significant increase from 1.174 +
0.45 to 1.356 + 0.622 (p < 0.05). There was an insignifi-
cant change in Group B, from 1.1 + 0.32 to 1.18 + 0.38
(p > 0.05). The average albumin level increased signifi-
cantly in both group A and B (p > 0.05) (Group A from
3.395 + 0.78 to 3.47 + 0.728; Group B from 3.34 + 0.82
to 3.53 + 0.80).
DISCUSSION
Development of ascites in patients with liver cirrho-
sis is a complex event. Two important factors that play a
role in the development of ascites are local and systemic
factors.2,3,4 Local factors include liver sinusoidal flow
and the capillary blood system of the intestines, which
are responsible for fluid accumulation in the abdominal
cavity. A systemic factor still believed to play a role is
the peripheral vasodilatation theory, which activates the
three vasoconstriction systems: the RAA system, arginin-
vasopressin, and the sympathetic nervous system. These
three systems cause fluid and sodium retention, causing
a reduction in glomerulofiltration, aggravating ascites.5,6
Administration of a low dose of captopril is expected to
inhibit these three vasoconstriction systems, thus improv-
ing natriuresis and diuresis.
The subjects of this study were 40 patients with liver
cirrhosis and ascites, with a male to female ratio of 1.1:1.
The age ranged from 25-64 years, the most being 40-49
years (35%). There was no significant difference be-
tween the two groups. The most common Child-Pugh
score found was a score B, which indicated moderate
liver disorder, followed by scores A and C.
A common complaint that occurred during treatment
with 3 x 6.25 mg/day of captopril for 2 weeks was dry
cough in 5 patients from group A (25%). In Group B,
one patient complained of cough, but the patient also
suffered from lung tuberculosis. Van Vliet found 1 out
of 8 patients with similar complaints after administration
of 18.75 mg/day of captopril for 3 months.13 Confusion
was found in 2 patients in group A (10%), pruritus in 2
patients (10%). Yorgensen found 2 patients with confu-
sion out of 4 respondents. Whether confusion was a side
effect of captopril, or whether it was caused by some-
thing else, was still uncertain.17
The systolic blood pressure of group A patients, who
received 3 x 6.25 mg /day of captopril for 2 weeks, was
significantly reduced (p < 0.001). Compared to group B,
which was not given captopril, the systolic blood pres-
sure did not undergo any significant change. Van Vliet
found an average systolic drop from 104.0 + 10.6 to 98.7
+ 8.6 during administration of 18.75 mg / day of captopril
for 11 – 14 days. According to Van Vliet, the patient’s
blood pressure should stabilize if the dose was reduced
to 2 x 6.25 mg/day.13 The patients’ diastolic blood pres-
Table 4 Laboratoric Parameter Pre- and Post-treatment 
(Group A) 
Variable Pre Post p 
Natrium (meq/L) 138.950 + 7.236 141.200 + 8.971 0.359 
Kalium (meq/l) 4.337 + 0.724 4.534 + 1.012 0.202 
Ureum (mg%) 42.5665 + 24.667 56.511 + 44.839 0.073 
Creatinin (mg%) 1.174 + 0.450 1.356 + 0.622 0.020 
Albumin (mg%)  3.395 + 0.78 3.470 + 0.728 0.419 
Table 5 Laboratoric Parameter Pre- and Post-treatment 
(Group B) 
Variable Pre Post p 
Natrim (meq/L) 141.85 + 6.62 137.25 + 6.41 0.061 
Kalium (meq/L) 4.1375 + 0.54 4.28 + 1.17 0.67 
Ureum (mg%) 32.99 + 12.46 44.09 + 20.98 0.01 
Creatinin (mg%) 1.10 + 0.32 1.18 + 0.38 0.28 
Albumin (mg%)  3.34 + 0.82 3.53 + 0.80 0.063 
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sure showed an insignificant drop. In general, the blood
pressure was reduced, but low dose captopril does not
cause hemodynamic imbalance.
The patients’ bodyweight and abdominal circumfer-
ence of the two groups both showed an insignificant re-
duction. Diuresis in those who received captopril was
significantly increased, while those who did not receive
captopril showed an insignificant increase. Natriuresis
in those receiving captopril was also significantly in-
creased, while those who did not receive captopril showed
an insignificant increase. Van Vliet also found a signifi-
cant increase in natriuresis after administration of
captopril.13 Addition of captopril in a diuretic regiment is
known as the nephron blockage seies. Combination of
loop diuretics and potassium-saving diuretics would pre-
vent potassium reabsorption at the distal tubuli. Stimula-
tion of the RAA system would increase sodium reab-
sorption along the proximal tubulus due to a high influ-
ence of angiotensin II. Administration of captopril re-
duces angiotensin II, thus decreasing sodium reabsorp-
tion and increasing natriuresis.13
The blood ureum level of Group A patients showed
an insignificant increase. The blood ureum level of Group
B patients increased significantly. Whether or not an in-
crease in blood ureum level shows reduced renal func-
tion that decreases natriuresis is still unclear. The crea-
tinine level of Group A patients showed a significant in-
crease, while for Group B, the increase was insignifi-
cant. There was no significant change in blood potas-
sium for both groups A and B. The blood sodium of pa-
tients from group A showed an insignificant increase,
while those from group B showed an insignificant de-
crease. The same thing occurred in Van Vliet’s study,
where no significant changes in blood sodium and potas-
sium levels were found after administration of captopril.13
The average blood albumin for both groups A and B
demonstrated an insignificant increase.
CONCLUSION
In this study, low dose captopril adjuvant in patients
with liver cirrhosis and ascites who have received stan-
dard therapy:
1. Increased natriuresis and improved diuretic response.
2. Reduced systolic blood pressure without causing
hemodynamic imbalance.
3. Reduced bodyweight and abdominal circumference,
even though not significantly.
4. Did not cause significant changes in electrolyte lev-
els.
5. Caused a side effect of cough in 25% of patients.
SUGGESTION
1. Further study with a larger sample is needed to
achieve better results.
2. There needs to be longer serial evaluation.
3. Captopril may be used as an alternative adjuvant
therapy in refractory ascites.
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